New combo therapy shows promise for Hard-to-Treat blood cancers
NCT ID NCT02005289
First seen Jan 04, 2026 · Last updated May 13, 2026 · Updated 21 times
Summary
This study tested a combination of two drugs, MOR00208 and lenalidomide, in 41 people with chronic lymphocytic leukemia (CLL) or related blood cancers. The goal was to see if the combination could shrink or control the cancer in patients who had not responded to prior treatments or who were unable to take standard therapy. The approach uses an antibody to target cancer cells and an immune-stimulating drug to help the body fight the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.